Novo Financial Statements From 2010 to 2024
| NONOF Stock | USD 109.00 0.70 0.64% |
Check Novo Nordisk financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novo Nordisk's main balance sheet or income statement drivers, such as , as well as many indicators such as . Novo financial statements analysis is a perfect complement when working with Novo Nordisk Valuation or Volatility modules.
Novo |
Novo Nordisk AS Company Return On Equity Analysis
Novo Nordisk's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Novo Nordisk Return On Equity | 0.72 |
Most of Novo Nordisk's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novo Nordisk AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Novo Nordisk AS has a Return On Equity of 0.72. This is 103.0% lower than that of the Healthcare sector and 101.97% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably lower than that of the firm.
Novo Nordisk AS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novo Nordisk's current stock value. Our valuation model uses many indicators to compare Novo Nordisk value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novo Nordisk competition to find correlations between indicators driving Novo Nordisk's intrinsic value. More Info.Novo Nordisk AS is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.30 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Novo Nordisk AS is roughly 3.32 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novo Nordisk's earnings, one of the primary drivers of an investment's value.About Novo Nordisk Financial Statements
Novo Nordisk stakeholders use historical fundamental indicators, such as Novo Nordisk's revenue or net income, to determine how well the company is positioned to perform in the future. Although Novo Nordisk investors may analyze each financial statement separately, they are all interrelated. For example, changes in Novo Nordisk's assets and liabilities are reflected in the revenues and expenses on Novo Nordisk's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Novo Nordisk AS. Please read more on our technical analysis and fundamental analysis pages.
Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. NOVO NORDISK is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novo Pink Sheet
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:Check out the analysis of Novo Nordisk Correlation against competitors. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.